Last reviewed · How we verify
NCT04605666
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Phase 2 trial testing CD19-CAR-T2 Cells in B Cell Leukemia in 77 participants. Completed in 31 December 2023.
30 June 2023
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 77 |
| Start date | 1 May 2020 |
| Primary completion | 30 June 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19-CAR-T2 Cells — full drug profile →
Conditions studied
- B Cell Leukemia — all drugs for B Cell Leukemia →
- B Cell Lymphoma — all drugs for B Cell Lymphoma →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 18 to 85, any sex, with B Cell Leukemia or B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chimeric antigen receptor T cells (CAR-T cells) has been recognized a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of third-generation anti-CD19 CAR T-cells (CD19-CAR-T2 Cells) in patients with CD19+ relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non Hodgkin Lymphoma (B-NHL).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F. · · 2023 · cited 29× · PMID 36875091 · DOI 10.3389/fimmu.2023.1063838 -
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.
He B, Lin R, Xu N, Qin L, et al · · 2025 · cited 7× · PMID 40426201 · DOI 10.1186/s12967-025-06608-x
Verify or expand the search:
- PubMed search for NCT04605666
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B Cell Leukemia
Currently open trials in the same condition.
- NCT06662227 — Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors · EARLY_PHASE1 · recruiting
- NCT01683279 — A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblasti · Phase 1 · active not recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04605666 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 20 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04605666.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing